Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/16157
Risk of Cancer in Family Members of Patients with Lynch-Like Syndrome
Identifiers
eISSN: 2072-6694
WOS ID: 000579043200001
Scopus EID: 2-s2.0-85090368369
PMID: 32784934
Embase PUI: L2004886829
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordAuthor
Pico, Maria Dolores; Sanchez-Heras, Ana Beatriz; Castillejo, Adela; Giner-Calabuig, Mar; Alustiza, Miren; Sanchez, Ariadna; Moreira, Leticia; Pellise, Maria; Castells, Antoni; Llort, Gemma; Yague, Carmen; Cajal, Teresa Ramon Y.; Gisbert-Beamud, Alexandra; Cubiella, Joaquin; Rivas, Laura; Herraiz, Maite; Garau, Catalina; Salces, Inmaculada; Carrillo-Palau, Marta; Bujanda, Luis; Lopez-Fernandez, Adria; Alvarez-Urturi, Cristina; Lopez, Maria Jesus; Alenda, Cristina; Zapater, Pedro; Lacueva, Francisco Javier; Balaguer, Francesc; Soto, Jose-Luis; Murcia, Oscar; Jover, RodrigoPublication date
2020-08Document type
research articleCitation
Pico Maria D, Sanchez-Heras AB, Castillejo A, Giner-Calabuig M, Alustiza M, Sanchez A, et al. Risk of Cancer in Family Members of Patients with Lynch-Like Syndrome. Cancers. 2020 Aug;12(8):2225.Abstract
Lynch syndrome (LS) is a common cause of hereditary colorectal cancer (CRC). Some CRC patients develop mismatch repair deficiency without germline pathogenic mutation, known as Lynch-like syndrome (LLS). We compared the risk of CRC in first-degree relatives (FDRs) in LLS and LS patients. LLS was diagnosed when tumors showed immunohistochemical loss of MSH2, MSH6, and PMS2; or loss of MLH1 withBRAFwild type; and/or noMLH1methylation and absence of pathogenic mutation in these genes. CRC and other LS-related neoplasms were followed in patients diagnosed with LS and LLS and among their FDRs. Standardized incidence ratios (SIRs) were calculated for CRC and other neoplasms associated with LS among FDRs of LS and LLS patients. In total, 205 LS (1205 FDRs) and 131 LLS families (698 FDRs) had complete pedigrees. FDRs of patients with LLS had a high incidence of CRC (SIR, 2.08; 95% confidence interval (CI), 1.56-2.71), which was significantly lower than that in FDRs of patients with LS (SIR, 4.25; 95% CI, 3.67-4.90;p< 0.001). The risk of developing other neoplasms associated with LS also increased among FDR of LLS patients (SIR, 2.04; 95% CI, 1.44-2.80) but was lower than that among FDR of patients with LS (SIR, 5.01, 95% CI, 4.26-5.84;p< 0.001). FDRs with LLS have an increased risk of developing CRC as well as LS-related neoplasms, although this risk is lower than that of families with LS. Thus, their management should take into account this increased risk.
Publisher version
https://dx.doi.org/10.3390/cancers12082225Keywords
colorectal cancerrisk
genetic
surveillance